This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dummer, R. Articles by Urosevic, M. Search for Related Content PubMed PubMed Citation Articles by Dummer, R. Articles by Urosevic, M.

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

Authors' Affiliations: ¹ Department of Dermatology, University Hospital Zurich, Zurich, Switzerland; ² Clinic for Dermatology, Venereology and Allergy, University Clinic Schleswig-Holstein, Kiel, Germany; ³ University Clinic and Health Center for Skin Diseases, Wurzburg, Germany; ⁴ Service de Dermatologie, Hôpital Ste Marguerite, Marseille, France; ⁵ Skin Cancer Unit, University Hospital Mannheim, Mannheim, Germany; ⁶ Department of Medical and Scientific Affairs, 3M Health Care, Loughborough, United Kingdom; and ⁷ Department of Medical and Scientific Affairs, 3M Pharmaceuticals, Saint Paul, Minnesota

Requests for reprints: Reinhard Dummer, Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zürich, Switzerland. Phone: 41-44-255-2588; Fax: 41-44-255-8988; E-mail: reinhard.dummer{at}usz.ch.

Purpose: A topical Toll-like receptor 7 (TLR7) agonist induces regression of cutaneous melanocytic neoplasms. We explored antitumor activity of a systemically administered TLR7 agonist, 852A, in patients with metastatic melanoma.

Experimental Design: We undertook a phase II, multicenter, open-label study in patients with chemotherapy-refractory metastatic melanoma. Patients received i.v. 852A, starting at 0.6 mg/m² and increasing to 0.9 mg/m² based on tolerance, thrice per week for 12 weeks. Clinical response was determined by Response Evaluation Criteria in Solid Tumors. Immune effects of 852A were monitored by measuring serum type I IFN and IP-10 together with assessment of immune cell markers in peripheral blood.

Results: Twenty-one patients were enrolled. Thirteen patients completed the initial 12-week treatment cycle, with two discontinuing for adverse events considered to be possibly related to study drug. Four (19%) patients had disease stabilization for >100 days. One patient had a partial remission after two treatment cycles, but progressed during the third. Dose-limiting toxicity was observed in two patients. Serum type I IFN and IP-10 increased in most patients on 852A administration. Serum type I IFN increases were greater after dosing with 852A 0.9 mg/m² than after 0.6 mg/m² (P = 0.009). The maximal increase in IP-10 compared with baseline correlated with the maximal increase in type I IFN (P = 0.003). In the eight patients with immune cell marker data, CD86 expression on monocytes increased significantly post-first dose (P = 0.007).

Conclusion: Intravenous 852A was well tolerated and induced systemic immune activation that eventually resulted in prolonged disease stabilization in some patients with stage IV metastatic melanoma who had failed chemotherapy.

This article has been cited by other articles:

				E. L. J. M. Smits, P. Ponsaerts, Z. N. Berneman, and V. F. I. Van Tendeloo The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy Oncologist, August 1, 2008; 13(8): 859 - 875. [Abstract] [Full Text] [PDF]